These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20388859)

  • 1. Crofelemer, a novel agent for treatment of secretory diarrhea.
    Crutchley RD; Miller J; Garey KW
    Ann Pharmacother; 2010 May; 44(5):878-84. PubMed ID: 20388859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea.
    Yeo QM; Crutchley R; Cottreau J; Tucker A; Garey KW
    Drugs Today (Barc); 2013 Apr; 49(4):239-52. PubMed ID: 23616951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crofelemer for the treatment of secretory diarrhea.
    Cottreau J; Tucker A; Crutchley R; Garey KW
    Expert Rev Gastroenterol Hepatol; 2012 Feb; 6(1):17-23. PubMed ID: 22149578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study.
    Macarthur RD; Hawkins TN; Brown SJ; Lamarca A; Clay PG; Barrett AC; Bortey E; Paterson C; Golden PL; Forbes WP
    HIV Clin Trials; 2013; 14(6):261-73. PubMed ID: 24334179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crofelemer: In HIV Associated Diarrhea and Secretory Diarrhea - A Patent Perspective.
    Biswal S
    Recent Pat Antiinfect Drug Discov; 2014; 9(2):136-43. PubMed ID: 25851117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients.
    Mangel AW; Chaturvedi P
    Digestion; 2008; 78(4):180-6. PubMed ID: 19092244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome.
    Nee J; Salley K; Ludwig AG; Sommers T; Ballou S; Takazawa E; Duehren S; Singh P; Iturrino J; Katon J; Lee HN; Rangan V; Lembo AJ
    Clin Transl Gastroenterol; 2019 Dec; 10(12):e00110. PubMed ID: 31800542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crofelemer: a review of its use in the management of non-infectious diarrhoea in adult patients with HIV/AIDS on antiretroviral therapy.
    Frampton JE
    Drugs; 2013 Jul; 73(10):1121-9. PubMed ID: 23807722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crofelemer, a novel agent for treatment of non-infectious diarrhea in HIV-infected persons.
    Chordia P; MacArthur RD
    Expert Rev Gastroenterol Hepatol; 2013 Sep; 7(7):591-600. PubMed ID: 24070150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy.
    Castro JG; Chin-Beckford N
    Expert Rev Clin Pharmacol; 2015; 8(6):683-90. PubMed ID: 26517110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS.
    Patel TS; Crutchley RD; Tucker AM; Cottreau J; Garey KW
    HIV AIDS (Auckl); 2013; 5():153-62. PubMed ID: 23888120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer.
    Van Sebille YZA; Gibson RJ; Wardill HR; Ball IA; Keefe DMK; Bowen JM
    Int J Cancer; 2018 Jan; 142(2):369-380. PubMed ID: 28921512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels.
    Tradtrantip L; Namkung W; Verkman AS
    Mol Pharmacol; 2010 Jan; 77(1):69-78. PubMed ID: 19808995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs.
    Guy M; Teixeira A; Shrier A; Meschter C; Bolognese J; Chaturvedi P
    PLoS One; 2024; 19(1):e0282769. PubMed ID: 38265977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crofelemer (Fulyzaq) for antiretroviral-induced diarrhea.
    Med Lett Drugs Ther; 2013 Jul; 55(1421):59-60. PubMed ID: 23863919
    [No Abstract]   [Full Text] [Related]  

  • 16. The Botanical Drug Substance Crofelemer as a Model System for Comparative Characterization of Complex Mixture Drugs.
    Kleindl PA; Xiong J; Hewarathna A; Mozziconacci O; Nariya MK; Fisher AC; Deeds EJ; Joshi SB; Middaugh CR; Schöneich C; Volkin DB; Forrest ML
    J Pharm Sci; 2017 Nov; 106(11):3242-3256. PubMed ID: 28743606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS.
    Holodniy M; Koch J; Mistal M; Schmidt JM; Khandwala A; Pennington JE; Porter SB
    Am J Gastroenterol; 1999 Nov; 94(11):3267-73. PubMed ID: 10566728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of loperamide in gastrointestinal disorders.
    Hanauer SB
    Rev Gastroenterol Disord; 2008; 8(1):15-20. PubMed ID: 18477966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Controlled clinical testing of an antidiarrheal].
    Dorn M
    MMW Fortschr Med; 2004 Aug; 146 Suppl 2():57-60. PubMed ID: 16739360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NPY Y2 receptor agonist PYY(3-36) inhibits diarrhea by reducing intestinal fluid secretion and slowing colonic transit in mice.
    Moriya R; Shirakura T; Hirose H; Kanno T; Suzuki J; Kanatani A
    Peptides; 2010 Apr; 31(4):671-5. PubMed ID: 19925840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.